2024
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMycobacterium tuberculosisRifampinTreatment OutcomeTuberculosisTuberculosis, Multidrug-ResistantConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalence
2022
vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding
Tran VN, Shams A, Ascioglu S, Martinecz A, Liang J, Clarelli F, Mostowy R, Cohen T, Abel zur Wiesch P. vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding. BMC Bioinformatics 2022, 23: 22. PMID: 34991453, PMCID: PMC8734216, DOI: 10.1186/s12859-021-04536-3.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBacteriaComputer SimulationDrug Resistance, BacterialModels, BiologicalConceptsOwn computational model
2020
Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones
Clarelli F, Palmer A, Singh B, Storflor M, Lauksund S, Cohen T, Abel S, Wiesch P. Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones. PLOS Computational Biology 2020, 16: e1008106. PMID: 32797079, PMCID: PMC7449454, DOI: 10.1371/journal.pcbi.1008106.Peer-Reviewed Original ResearchConceptsDose levelsAntibiotic efficacyDrug-target bindingDose-response relationshipBeta-lactams ampicillinTime-kill curvesDose-response curveNovel resistance mutationsMeasurable biochemical parametersClinical isolatesAntibiotic dose-response curvesAntibiotic actionResistance mutationsBiochemical parameters
2017
Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers
Kunkel A, Lewnard JA, Pitzer VE, Cohen T. Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00026-17. PMID: 28533237, PMCID: PMC5527623, DOI: 10.1128/aac.00026-17.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsAntibiotic ProphylaxisCholeraDisease OutbreaksDrug Resistance, BacterialHaitiHumansModels, TheoreticalRiskUnited NationsVibrio choleraeConceptsDrug-resistant infectionsAntimicrobial chemoprophylaxisDrug-sensitive infectionsDrug resistance generationCholera importationChemoprophylaxisDrug resistanceImportation eventsInfectionAntibiotic resistanceAntimicrobial resistance risksRiskRelative benefitsResistance generationCholeraPotential resistance risksPotential benefitsResistance riskProphylaxisPrevalenceUsing Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies
Wiesch P, Clarelli F, Cohen T. Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies. PLOS Computational Biology 2017, 13: e1005321. PMID: 28060813, PMCID: PMC5257006, DOI: 10.1371/journal.pcbi.1005321.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBacterial InfectionsBacterial Physiological PhenomenaComputational BiologyDrug Resistance, BacterialHumansKineticsMicrobial Sensitivity TestsModels, BiologicalConceptsOptimal dosingTreatment strategiesOnset of actionAntibiotic treatment strategiesAntibiotic concentrationsOptimal therapyFrequent dosingHigh dosesBacterial infectionsDrug concentrationsDosingBacterial replicationAntibioticsPhysiological fluctuationsAntibiotic effectCellsHIVBacterial growthTherapyCancerInfectionMalariaDoses
2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic
Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016, 30: 2715-2723. PMID: 27782966, PMCID: PMC5089846, DOI: 10.1097/qad.0000000000001235.Peer-Reviewed Original ResearchConceptsContinuous isoniazid preventive therapyIsoniazid preventive therapyIsoniazid-resistant tuberculosisTB epidemicPreventive therapyEffective TB treatmentLatent TB infectionTB drug resistanceTransmission dynamic modelTB infectionMortality benefitTB treatmentHIV controlHIV incidenceTB incidenceTB transmissionCase findingDrug resistanceIncidenceTuberculosisInitial benefitPLHIVHIVTherapyEpidemicAssessing the utility of Xpert® MTB/RIF as a screening tool for patients admitted to medical wards in South Africa
Heidebrecht CL, Podewils LJ, Pym AS, Cohen T, Mthiyane T, Wilson D. Assessing the utility of Xpert® MTB/RIF as a screening tool for patients admitted to medical wards in South Africa. Scientific Reports 2016, 6: 19391. PMID: 26786396, PMCID: PMC4726405, DOI: 10.1038/srep19391.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCoinfectionDrug Resistance, BacterialFemaleHIV InfectionsHumansMaleMass ScreeningMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisNucleic Acid Amplification TechniquesReproducibility of ResultsRifampinSouth AfricaTuberculosis, Multidrug-ResistantYoung AdultConceptsChest X-rayMTB/RIFMedical wardsScreening toolAdditional TB casesInfection control actionsUtility of GeneXpertTB/HIVConsecutive adult patientsProportion of patientsRifampicin-resistant tuberculosisDrug-resistant tuberculosisLarge public hospitalTB diseaseAdult patientsStandard careTB casesTB screeningMedical admissionsMedical chartsHospital inpatientsSputum specimensGeneXpertPatientsRifampicin resistance
2015
Data for action: collection and use of local data to end tuberculosis
Theron G, Jenkins HE, Cobelens F, Abubakar I, Khan AJ, Cohen T, Dowdy DW. Data for action: collection and use of local data to end tuberculosis. The Lancet 2015, 386: 2324-2333. PMID: 26515676, PMCID: PMC4708262, DOI: 10.1016/s0140-6736(15)00321-9.Peer-Reviewed Original ResearchMeSH KeywordsBacterial Typing TechniquesData CollectionDrug Resistance, BacterialEthics, MedicalGeographic Information SystemsGeographic MappingHumansMycobacterium tuberculosisTuberculosisHow competition governs whether moderate or aggressive treatment minimizes antibiotic resistance
Colijn C, Cohen T. How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance. ELife 2015, 4: e10559. PMID: 26393685, PMCID: PMC4641510, DOI: 10.7554/elife.10559.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBacteriaBacterial InfectionsDrug Resistance, BacterialModels, Theoretical
2014
Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach
Langley I, Lin HH, Egwaga S, Doulla B, Ku CC, Murray M, Cohen T, Squire SB. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. The Lancet Global Health 2014, 2: e581-e591. PMID: 25304634, DOI: 10.1016/s2214-109x(14)70291-8.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioHigh incremental costIncremental costLED fluorescence microscopyCost-effectiveness ratioPay thresholdsFull rolloutContext of TanzaniaCost-effective optionHealth policy formulationPolicy formulationDifferent diagnostic optionsIntegrated modelling approachModelling approachAdditional costHealth systemCostAlternative diagnosticsIntegrated modelXpert MTB/RIFPopulation effectsMTB/RIFPresumptive tuberculosis casesWillingnessUse of Xpert
2013
Isoniazid-resistant Tuberculosis in Children
Yuen CM, Tolman AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-resistant Tuberculosis in Children. The Pediatric Infectious Disease Journal 2013, 32: e217-e226. PMID: 23348808, PMCID: PMC3709006, DOI: 10.1097/inf.0b013e3182865409.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntitubercular AgentsChildChild, PreschoolDrug Resistance, BacterialHumansInfantIsoniazidMycobacterium tuberculosisTuberculosisConceptsIsoniazid-resistant tuberculosisLatent tuberculosis infectionTuberculosis diseaseTuberculosis infectionIsoniazid resistancePediatric tuberculosis patientsTreatment of childrenIsoniazid-resistant strainsReports of childrenEffective regimensTuberculosis patientsTuberculosis treatmentAppropriate treatmentInclusion criteriaMedian proportionSystematic reviewRifampin resistanceDiseaseTuberculosisRegimensChildrenTreatmentInfectionIsoniazidHigher proportion
2012
Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLOS Medicine 2012, 9: e1001347. PMID: 23185139, PMCID: PMC3502465, DOI: 10.1371/journal.pmed.1001347.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBCost-effectiveness ratioInitial diagnosisXpert MTB/RIF testMTB/RIF testXpert MTB/RIFIntroduction of XpertTB natural historyTB-HIV coinfectionMultidrug-resistant tuberculosisHigh HIV prevalenceMTB/RIFHealth system costsImplementation of XpertHealth impactsPopulation health impactCost-effectiveness resultsLong-term transmission dynamicsWorld Health OrganizationAntiretroviral therapyTB casesTB deathsTB morbidityHIV prevalenceRIF testOutcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 812-6. PMID: 22507372, PMCID: PMC3786434, DOI: 10.5588/ijtld.11.0637.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsChi-Square DistributionDrug Resistance, BacterialDrug Therapy, CombinationEthambutolFemaleGeorgia (Republic)HumansIsoniazidLogistic ModelsMaleMicrobial Sensitivity TestsMiddle AgedMultivariate AnalysisMycobacterium tuberculosisPredictive Value of TestsPyrazinamideRetrospective StudiesRifampinRisk AssessmentRisk FactorsSputumTime FactorsTreatment OutcomeTuberculosisConceptsPulmonary tuberculosisPrevious treatmentOutcomes of patientsPulmonary TB patientsSubset of patientsRetrospective record reviewForms of tuberculosisFirst-line drugsHigh TB ratesDrug-resistant formsLower ratesLow tuberculosisTB patientsTuberculosis patientsOptimal management strategyTreatment regimenRecord reviewTB ratesTreatment successTreatment outcomesCountry of GeorgiaPatientsIsoniazid resistanceTuberculosisDrug resistance
2011
Models to understand the population-level impact of mixed strain M. tuberculosis infections
Sergeev R, Colijn C, Cohen T. Models to understand the population-level impact of mixed strain M. tuberculosis infections. Journal Of Theoretical Biology 2011, 280: 88-100. PMID: 21514304, PMCID: PMC3111980, DOI: 10.1016/j.jtbi.2011.04.011.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsDrug Resistance, BacterialHumansModels, TheoreticalMutationMycobacterium tuberculosisSpecies SpecificityTuberculosisConceptsDrug-resistant strainsMixed strain infectionsStrain infectionDrug-sensitive tuberculosisDrug-resistant tuberculosisM. tuberculosis infectionLower basic reproductive numberDrug-resistant infectionsTuberculosis patientsTuberculosis infectionTreatment successDrug-resistant bacteriaFuture burdenLong-term effectsStrain-specific differencesDrug resistanceInfectionPopulation-level impactTuberculosisM. tuberculosisMixed infectionsMycobacterium tuberculosisBasic reproductive numberCo-infected hostsSmall subpopulationDrug Resistance Surveillance in Resource-Poor Settings: Current Methods and Considerations for TB, HIV, and Malaria
Hedt BL, Laufer MK, Cohen T. Drug Resistance Surveillance in Resource-Poor Settings: Current Methods and Considerations for TB, HIV, and Malaria. American Journal Of Tropical Medicine And Hygiene 2011, 84: 192-199. PMID: 21292884, PMCID: PMC3029167, DOI: 10.4269/ajtmh.2011.10-0363.Peer-Reviewed Original Research
2010
The Prevalence and Drug Sensitivity of Tuberculosis among Patients Dying in Hospital in KwaZulu-Natal, South Africa: A Postmortem Study
Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D. The Prevalence and Drug Sensitivity of Tuberculosis among Patients Dying in Hospital in KwaZulu-Natal, South Africa: A Postmortem Study. PLOS Medicine 2010, 7: e1000296. PMID: 20582324, PMCID: PMC2889914, DOI: 10.1371/journal.pmed.1000296.Peer-Reviewed Original ResearchConceptsTime of deathTuberculosis treatmentLimited autopsiesM. tuberculosisMultidrug-resistant bacilliCulture-positive tuberculosisInitiation of treatmentMultidrug-resistant tuberculosisHIV-positive individualsMajority of decedentsRespiratory tract secretionsHigh HIV prevalenceSecond-line antibioticsNeedle core biopsySingle public hospitalDiagnosis of tuberculosisAcid-fast bacilliCause of deathNew public health approachPublic health approachMagnitude of deathsFatal courseAdult inpatientsStudy cohortHIV prevalenceEstimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study
Cohen T, Hedt BL, Pagano M. Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study. BMC Public Health 2010, 10: 355. PMID: 20565947, PMCID: PMC2898828, DOI: 10.1186/1471-2458-10-355.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiasData CollectionDrug Resistance, BacterialFemaleHumansIndiaMaleModels, TheoreticalPublic SectorTuberculosis, Pulmonary
2008
Latent Coinfection and the Maintenance of Strain Diversity
Colijn C, Cohen T, Murray M. Latent Coinfection and the Maintenance of Strain Diversity. Bulletin Of Mathematical Biology 2008, 71: 247. PMID: 19082663, PMCID: PMC2652765, DOI: 10.1007/s11538-008-9361-y.Peer-Reviewed Original ResearchNo coexistence for free: Neutral null models for multistrain pathogens
Lipsitch M, Colijn C, Cohen T, Hanage WP, Fraser C. No coexistence for free: Neutral null models for multistrain pathogens. Epidemics 2008, 1: 2-13. PMID: 21352747, PMCID: PMC3099423, DOI: 10.1016/j.epidem.2008.07.001.Peer-Reviewed Original ResearchDrug Resistance, BacterialEcosystemHumansModels, BiologicalPneumococcal InfectionsStreptococcus pneumoniaeSeasonality of Antibiotic-Resistant Streptococcus pneumoniae That Causes Acute Otitis Media: A Clue for an Antibiotic-Restriction Policy?
Dagan R, Barkai G, Givon-Lavi N, Sharf AZ, Vardy D, Cohen T, Lipsitch M, Greenberg D. Seasonality of Antibiotic-Resistant Streptococcus pneumoniae That Causes Acute Otitis Media: A Clue for an Antibiotic-Restriction Policy? The Journal Of Infectious Diseases 2008, 197: 1094-1102. PMID: 18419528, PMCID: PMC2652754, DOI: 10.1086/528995.Peer-Reviewed Original Research